Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
74°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Lantheus Holdings, Inc.
< Previous
1
2
Next >
Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
August 20, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Reports Second Quarter 2024 Financial Results
July 31, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
July 17, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease
July 15, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Welcomes CMS’ Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
July 10, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Appoints Jamie Spaeth as Chief People Officer
July 08, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
June 27, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform
June 03, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus to Present at the William Blair 44th Annual Growth Stock Conference
May 28, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Announces Executive Appointments to Accelerate Innovation
May 15, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Reports First Quarter 2024 Financial Results
May 02, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
April 18, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
March 05, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
March 04, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
February 28, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
February 22, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
February 13, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
February 08, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Announces CEO Succession Plan
January 23, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
January 11, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
January 09, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
January 09, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
December 18, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus to Present at the Jefferies London Healthcare Conference
November 08, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time
October 19, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
September 01, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus to Present at the Wells Fargo Healthcare Conference
August 31, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
August 03, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Tickers
LNTH
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.